A 48-year-old on-the-go mom and a full-time consultant who cares for her growing children. She never smoked, was previously healthy, and had no family history of cancer. She initially presented to her doctor with:
- Presentation: 2-month history of dysphagia, a worsening dry cough, and fatigue
- Chest x-ray and CT scan: revealed left lower lobe and multiple bilateral lung nodules
- Core biopsy: right cervical lymph node biopsy confirmed a diagnosis of NSCLC (adenocarcinoma)
- MRI of the brain: No evidence of intracranial metastases
- Biomarker test results:
- NGS sequencing demonstrated ALK rearrangement
- PD-L1 expression by IHC: 70%
Based on her symptoms and test results, her doctor explained to her she had ALK+ mNSCLC.
For Jill, balancing efficacy, tolerability, and pill burden is essential1,2
Up to 75% of patients develop brain mets during the course of their disease3,4,5
Potential effects can include cognitive issues such as speech problems6,7,8
Jill needs to stay on top of her competing priorities at home and at work as long as possible. She needs a treatment option with demonstrated systemic and CNS efficacy.6,8,9
Patients like Jill are being diagnosed younger (median age 51 years old) and staying on treatment longer (6.75 years)10,11,a
aBased on a natural history study of Stage IV ALK-rearranged NSCLC conducted from 2009 through November 2017 (N=110).
Jill can't afford to miss work. She needs a treatment option with generally tolerable side effects so she can operate at her best each day.1
Certain ALK inhibitors require up to 2,920 tablets/capsules per year, while others require just 3651
Jill’s busy schedule creates challenges with taking up to 8 pills a day and figuring out how to pair each dose with food. A simple dosing schedule could help her routine stay on track.1,12,13
"I want to live a long life, but I don't want the treatment to define me." - Larissa
Hear from a real patient about how ALUNBRIG fits into their life
Larissa is a real ALUNBRIG patient
National Comprehensive Cancer Network® (NCCN®): recommends brigatinib as a Category 1 preferred first-line treatment option for ALK+ metastatic NSCLC14,a,b,c
Make ALUNBRIG the first-line treatment for your patients with ALK+ mNSCLC:
Proven First-Line Efficacy2
First-line results in patients with ALK+ mNSCLC with and without brain metastases at baseline
A well-established safety profile with long-term tolerability
Helpful information on the one-tablet, once-daily recommended dosage
aWhen an ALK rearrangement is discovered prior to first-line systemic therapy.2
bThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories.
cSee the NCCN Guidelines® for detailed recommendations, including other preferred treatment options.
ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; mNSCLC, metastatic NSCLC; NSCLC, non-small cell lung cancer.